Autres langues Verastem, Inc.

Actions

VSTM

US92337C2035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
7,550 ^USD	+3,14%		-0,92%	-2,20%

17/09	Verastem, Inc. : Opinion positive de Wolfe Research	ZM
14/09	L'ANR de RTW Biotech progresse de 15% grâce à la performance des investissements cotés	AN

Autres langues

14/09	RTW Biotech NAV rises 15% as public investments drive returns
08/09	Verastem Oncology Unveils New Clinical Data Highlighting The Best-In-Class Potential Of VS-7375, An Oral KRAS G12D (ON/OFF) Inhibitor Across Pancreatic, Lung, And Colorectal Cancers
08/09	Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
02/09	Verastem Oncology to Participate in Upcoming September Investor Conferences
07/08	Verastem, Inc. Amends Note Purchase Agreement to Establish New Series of Senior Secured Revenue Notes Up to $75 Million
07/08	Verastem : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
06/08	Verastem: Q2 Earnings Snapshot
06/08	Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
28/07	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
28/07	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
23/07	Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
22/07	Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer
22/07	Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
02/07	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell Small Cap Comp Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000 Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 3000E Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell Microcap Value Benchmark Index
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 2500 Value Benchmark
29/06	Verastem, Inc.(NasdaqCM:VSTM) dropped from Russell 2000 Value Benchmark
24/06	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says
23/06	Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
23/06	VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
23/06	Verastem Oncology Demonstrates Clinical Activity of Vs-7375 in Target-D 101 Phase 1/2 Clinical Trial in Patients with Advanced Kras G12d-Mutated Solid Tumors